U.S. Markets closed
  • S&P 500

    3,923.68
    -165.17 (-4.04%)
     
  • Dow 30

    31,490.07
    -1,164.52 (-3.57%)
     
  • Nasdaq

    11,418.15
    -566.37 (-4.73%)
     
  • Russell 2000

    1,774.85
    -65.45 (-3.56%)
     
  • Crude Oil

    109.28
    -3.12 (-2.78%)
     
  • Gold

    1,815.30
    -3.60 (-0.20%)
     
  • Silver

    21.42
    -0.33 (-1.52%)
     
  • EUR/USD

    1.0469
    -0.0086 (-0.8166%)
     
  • 10-Yr Bond

    2.8860
    -0.0820 (-2.76%)
     
  • Vix

    30.96
    +4.86 (+18.62%)
     
  • GBP/USD

    1.2341
    -0.0152 (-1.2143%)
     
  • USD/JPY

    128.1850
    -1.1730 (-0.9068%)
     
  • BTC-USD

    29,190.47
    -953.12 (-3.16%)
     
  • CMC Crypto 200

    650.57
    -20.11 (-3.00%)
     
  • FTSE 100

    7,438.09
    -80.26 (-1.07%)
     
  • Nikkei 225

    26,911.20
    +251.45 (+0.94%)
     

Biogen scraps two late-stage Alzheimer's trials

  • Oops!
    Something went wrong.
    Please try again later.
  • Oops!
    Something went wrong.
    Please try again later.
In this article:
  • Oops!
    Something went wrong.
    Please try again later.
  • Oops!
    Something went wrong.
    Please try again later.

Sept 13 (Reuters) - Biogen Inc and partner Eisai Co Ltd said on Friday they would abandon two late-stage trials testing their experimental treatment, elenbecestat, for patients with early Alzheimer's disease.

The companies said the decision was based on the results of a safety review conducted by a data safety monitoring board, which recommended to discontinue the trials due to unfavorable risk-benefit ratio.

The announcement comes months after the companies said they were ending two late-stage trials of another experimental Alzheimer's disease drug, aducanumab.

The company's shares fell 1.6% to $228.50 in premarket trading. (Reporting by Manojna Maddipatla in Bengaluru Editing by Saumyadeb Chakrabarty)